HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Keros Therapeutics (NASDAQ:KROS) and maintained a $100 price target.
June 18, 2024 | 10:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Keros Therapeutics and maintained a $100 price target.
The reiteration of a Buy rating and the maintenance of a $100 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100